Biology of Gastrointestinal Stromal Tumors: KIT Mutations and Beyond

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the digestive tract. Aspects of the morphology and immunophenotype in GISTs resemble those in the interstitial cells of Cajal (ICC), which are a specialized cell type responsible for coordinating peristaltic activity throughout the gastrointestinal tract. Therefore, it is possible that GISTs result from transformation of nonneoplastic progenitor cells that would normally differentiate towards an ICC endpoint. Activation of the KIT receptor tyrosine kinase is required for differentiation and proliferation of nonneoplastic ICC, and oncogenic KIT mutations are a crucial event in the development of most GISTs. These mutations can involve either the extracellular or intracellular domains of the KIT receptor, giving rise to conformational changes that enable constitutive, ligand-independent, activation of the KIT protein. Oncogenic KIT activation leads to phosphorylation of various substrate proteins and, in turn, to activation of signal transduction cascades regulating cell proliferation, apoptosis, chemotaxis, and adhesion. Recently, a small molecule tyrosine kinase inhibitor (STI571, imatinib mesylate, Gleevec®) directed against the enzymatic (kinase) domain of the KIT protein was found to produce dramatic clinical responses as monotherapy for metastatic GISTs. This review focuses on the biological and molecular genetic principles of GISTs, and particularly the role of mutant KIT as a therapeutic target.

[1]  Y. Matsuzawa,et al.  Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.

[2]  O. GonzaloMéndez,et al.  Gastric stromal tumors. , 1987, The Nebraska medical journal.

[3]  S. Lev,et al.  Structure‐function analyses of the kit receptor for the steel factor , 1993, Stem cells.

[4]  E Leonard,et al.  Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. , 2001, Blood.

[5]  C. Fletcher,et al.  Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. , 2002, American journal of clinical pathology.

[6]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[7]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[8]  L. Sobin,et al.  KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[9]  S. Hirota,et al.  Disturbed pyloric motility in Ws/Ws mutant rats due to deficiency of c‐kit expressing interstitial cells of Cajal , 1998, Pathology international.

[10]  M. Klüppel,et al.  Developmental origin and kit‐dependent development of the interstitial cells of cajal in the mammalian small intestine , 1998, Developmental dynamics : an official publication of the American Association of Anatomists.

[11]  J. Gutkind,et al.  Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF. , 1997, Biochemical and biophysical research communications.

[12]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[13]  T. Nishida,et al.  Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.

[14]  J. Reilly,et al.  c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia , 1999, British journal of haematology.

[15]  C. Deberry,et al.  Stat1 associates with c-kit and is activated in response to stem cell factor. , 1997, The Biochemical journal.

[16]  A. Sandberg,et al.  Two cases of low-grade gastric leiomyosarcoma with monosomy 14 as the only change. , 1996, Cancer genetics and cytogenetics.

[17]  D. Gardiol,et al.  Gastrointestinal stromal tumours: an immunohistochemical study of 165 cases , 1991, Histopathology.

[18]  Jonathan J. Lewis,et al.  Gastrointestinal Stromal Tumors and Leiomyosarcoma of the Abdomen and Retroperitoneum: A Clinical Comparison , 2001, Annals of Surgical Oncology.

[19]  Y. Matsuzawa,et al.  Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. , 1994, Blood.

[20]  A. Kuraishi,et al.  Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. , 2001, Gastroenterology.

[21]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[22]  E. Wardelmann,et al.  c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant , 2002, Modern Pathology.

[23]  Yeng-Chung Chang,et al.  Smooth muscle tumors of the gastrointestinal tract , 2001 .

[24]  D. Metcalfe,et al.  Kit signal transduction. , 2000, Hematology/oncology clinics of North America.

[25]  C. Fletcher,et al.  Gastrointestinal stromal tumours: Correlation of immunophenotype with clinicopathological features , 1991, The Journal of pathology.

[26]  A. Perez-Atayde,et al.  Neuroectodermal differentiation of the gastrointestinal tumors in the Carney triad. An ultrastructural and immunohistochemical study. , 1993, The American journal of surgical pathology.

[27]  A. Bernstein,et al.  Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1 , 1996, Nature Genetics.

[28]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[29]  T Pawson,et al.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[31]  Duc Hung Le,et al.  SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain , 1998, Molecular and Cellular Biology.

[32]  John Malysz,et al.  W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.

[33]  A. Joachimiak,et al.  Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Lloyd,et al.  Cell markers in gastrointestinal stromal tumors. , 1988, Human pathology.

[35]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[36]  S. Majumder,et al.  c-kit protein, a transmembrane kinase: identification in tissues and characterization , 1988, Molecular and cellular biology.

[37]  C. Turc‐Carel,et al.  Three possible cytogenetic subgroups of leiomyosarcoma. , 1989, Cancer genetics and cytogenetics.

[38]  Y. Matsuzawa,et al.  Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. , 1995, International archives of allergy and immunology.

[39]  L. Sobin,et al.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.

[40]  S. Hirota,et al.  Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. , 2000, The American journal of surgical pathology.

[41]  A. Kovatich,et al.  CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[42]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Hirota,et al.  Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. , 1995, Gastroenterology.

[44]  S. Hirota,et al.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.

[45]  Y. Ma,et al.  Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. , 1999, The Journal of investigative dermatology.

[46]  L. Sobin,et al.  Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. , 1999, The American journal of surgical pathology.

[47]  M. Heinrich,et al.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.

[48]  L. Regan,et al.  Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.

[49]  S. Hirota,et al.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.

[50]  S. Hirota,et al.  Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[51]  Y. Satow,et al.  c‐kit point mutation of extracellular domain in patients with myeloproliferative disorders , 1995, British journal of haematology.

[52]  D. Linnekin,et al.  Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.

[53]  T. Lehnert.  Gastrointestinal sarcoma (GIST)--a review of surgical management. , 1998, Annales chirurgiae et gynaecologiae.

[54]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[55]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[56]  C. Antonescu,et al.  Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Atfi,et al.  The oncogenic TEL/PDGFRβ fusion protein induces cell death through JNK/SAPK pathway , 1999, Oncogene.

[58]  C. Heldin,et al.  Activation of the human c‐kit product by ligand‐induced dimerization mediates circular actin reorganization and chemotaxis. , 1991, The EMBO journal.

[59]  L. Ashman,et al.  The biology of stem cell factor and its receptor C-kit. , 1999, The international journal of biochemistry & cell biology.

[60]  S Torihashi,et al.  Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype. , 1999, Gastroenterology.

[61]  J. Darnell,et al.  Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  C. Marshall,et al.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors , 1999, Oncogene.

[63]  C. Capella,et al.  Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa , 2001, Cancer.

[64]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[65]  A. Andrén-sandberg,et al.  Recurrent chromosome aberrations in abdominal smooth muscle tumors. , 1992, Cancer genetics and cytogenetics.

[66]  M. Mazur,et al.  Gastric stromal tumors Reappraisal of histogenesis , 1983, The American journal of surgical pathology.

[67]  O. Katoh,et al.  c-kit Point mutation in patients with myeloproliferative disorders. , 1997, Leukemia & lymphoma.

[68]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[69]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[70]  S. Hirota,et al.  A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. , 1998, Gastroenterology.

[71]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.